PriceTargets.com logo

Medicus Pharma - MDCX Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 172.11%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 2 Strong Buy Ratings
$4.41 As of 05/2/2025 05:00 PM ET
▲ +0.09 (2.08%)

This chart shows the closing price for MDCX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarApr$4.41Closing price on 05/02/25:
Get New Medicus Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDCX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDCX

Analyst Price Target is $12.00
▲ +172.11% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Medicus Pharma in the last 3 months. The average price target is $12.00, with a high forecast of $14.00 and a low forecast of $10.00. The average price target represents a 172.11% upside from the last price of $4.41.

This chart shows the closing price for MDCX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
11/242/255/255/26$1.62$4.71$7.81$11$14Closing price on 05/02/25: $4.41High$14.00Average$12.00Low$10.00




Current Consensus is Strong Buy

The current consensus among 4 contributing investment analysts is to buy (strong buy) stock in Medicus Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2025
  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2025

Latest Recommendations

  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/28/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
4/21/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
4/14/2025D Boral CapitalUpgradeStrong-Buy
4/14/2025D. Boral CapitalInitiated CoverageBuy$14.00
12/23/2024Brookline Capital ManagementUpgradeStrong-Buy
12/17/2024Maxim GroupInitiated CoverageBuy$10.00
(Data available from 5/3/2020 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2025
  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2025
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2025
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2025

Current Sentiment

  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Medicus Pharma logo
Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.
Read More

Today's Range

Now: $4.41
Low: $4.12
High: $4.75

50 Day Range

MA: $3.61
Low: $2.61
High: $4.52

52 Week Range

Now: $4.41
Low: $1.80
High: $6.00

Volume

45,584 shs

Average Volume

51,711 shs

Market Capitalization

$59.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Medicus Pharma?

The following Wall Street analysts have issued stock ratings on Medicus Pharma in the last twelve months: Brookline Capital Management, D Boral Capital, D. Boral Capital, and Maxim Group.
View the latest analyst ratings for MDCX.

What is the current price target for Medicus Pharma?

0 Wall Street analysts have set twelve-month price targets for Medicus Pharma in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 172.1%. D. Boral Capital has the highest price target set, predicting MDCX will reach $14.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $10.00 for Medicus Pharma in the next year.
View the latest price targets for MDCX.

What is the current consensus analyst rating for Medicus Pharma?

Medicus Pharma currently has 2 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for MDCX.

What other companies compete with Medicus Pharma?

Other companies that are similar to Medicus Pharma include Humacyte, Amarin, Ocugen, Bright Minds Biosciences and enGene. Learn More about companies similar to Medicus Pharma.

How do I contact Medicus Pharma's investor relations team?

The company's listed phone number is 732-300-3046 and its investor relations email address is ir@medicuspharma.com. The official website for Medicus Pharma is www.medicuspharma.com. Learn More about contacing Medicus Pharma investor relations.